$ALRN News
Last published 1y ago
- 1y agoRNTXALRNAileron Therapeutics Announces Rebranding to Rein TherapeuticsPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company...
- 1y agoALRNAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsPR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 1y agoALRNAileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)PR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaPR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisPR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)PR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics to Present at the 8th Annual IPF SummitPR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsPR NewswireAileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a pipeline of potential first-in-class...
- 2y agoALRNAileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferencePR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
- 2y agoALRNAileron Therapeutics to be Included in the Russell Microcap® IndexPR NewswireAileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class...
- 2y agoALRNAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewswireAnnounced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results
- 2y agoALRNAileron Therapeutics to Present at Two Upcoming Investor ConferencesGlobeNewswireAUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 2y agoALRNAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionGlobeNewswireAUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 2y agoALRNAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionGlobeNewswireAUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 2y agoALRNAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)GlobeNewswireLow-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative
- 2y agoALRNAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswireTopline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway
- 2y agoALRNAileron Therapeutics Announces CEO TransitionGlobeNewswireCurrent President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan
- 2y agoALRNAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventGlobeNewswireWALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 2y agoALRNAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024GlobeNewswireWALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 3y agoALRNAileron Therapeutics Announces Acquisition of Lung TherapeuticsPR NewswireAileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held...
- 3y agoALRNAileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic AlternativesGlobeNewswireBOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer
- 3y agoALRNAileron Therapeutics Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireBOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today
- 4y agoALRNAileron Therapeutics Announces a 1-for-20 Reverse Stock SplitGlobeNewswireBOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today
- 4y agoALRNAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewswireActivated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023Presented healthy volunteer study results at
- 4y agoALRNAileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International ConferenceGlobeNewswirep53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss)Study showed
- 4y agoALRNAileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022GlobeNewswireNew ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily arrested t
- 4y agoALRNAileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare ConferenceGlobeNewswireBOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D.,
- 4y agoALRNAileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that a pre-recorded corpo
- 4y agoALRNAileron Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewswireCompany continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trial Extended cash runway expected to support operations through end of 1Q 2024 Prese
- 4y agoALRNAileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast CancerGlobeNewswireEnhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mu
- 4y agoALRNAileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022GlobeNewswireBOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that Manuel Aivado, M.D.,
- 4y agoALRNAileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast CancerGlobeNewswirePatients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALR
- 4y agoALRNAileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast CancerGlobeNewswireAileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone m
- 4y agoALRNAileron Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireBOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., P
- 4y agoALRNAileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022GlobeNewswireBOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that it will host a virtual
- 4y agoALRNAileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual MeetingGlobeNewswireTaxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicle
- 4y agoALRNAileron Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewswireOn track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of A
- 4y agoALRNAileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical OperationsGlobeNewswireMr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients
- 4y agoALRNAileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewswireSeveral anticipated catalysts in 2022 aim to advance Aileron's vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b trial in p53
- 4y agoALRNAileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth ConferenceGlobeNewswireBOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients' lives, announced today that
- 4y agoALRNAileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key MilestonesGlobeNewswirePlans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track fo
- 4y agoALRNAileron Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D.,
- 4y agoALRNBMCSINNDLVO+4CEO Presenting on the Emerging Growth Conference on January 5 Register NowGlobeNewswireMIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 22nd Emergi
- 4y agoALRNAileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. GrubbsGlobeNewswireBOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member of the company's Scientific Advisory Board since
- 5y agoALRNAileron Therapeutics Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewswireContinues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results i
- 5y agoALRNAileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced ToxicityGlobeNewswire-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's activation of p21-induced cell cycle arrestin murine b
- 5y agoALRNAileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021GlobeNewswireBOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical
- 5y agoALRNIVCMDVLRKLY+1Thinking about buying stock in Aileron Therapeutics, Invacare, Medavail, Rockley Photonics, or Uranium Royalty?PR NewswireNEW YORK, Sept. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALRN, IVC, MDVL, RKLY, and UROY.
- 5y agoALRNAileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924's Best-in-Class Potential as a Chemoprotective AgentGlobeNewswireFinal results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924's ability to reduce neutropenia, thrombocytopenia and anemia caused by chemotherapy, as well as the need fo
- 5y agoALRNAileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924GlobeNewswirePreliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic effects Final data from completed Phase 1b study in patients